We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Glycated Hemoglobin Screening Reveals Undiagnosed Diabetes

By LabMedica International staff writers
Posted on 15 Oct 2020
Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is a form of diabetes that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. More...
Common symptoms include increased thirst, frequent urination, and unexplained weight loss.

Threshold for diagnosis of diabetes is based on the relationship between results of glucose tolerance tests, fasting glucose or glycated hemoglobin (HbA1c) and complications such as retinal problems. HbA1c has the advantages that fasting is not required and results are more stable but has the disadvantage that the test is more costly than measurement of blood glucose.

Scientists at the University of Exeter Medical School (Exeter, UK) analyzed data from 216,644 UK Biobank participants with primary care records available and an HbA1c measured at recruitment. They defined participants without a diagnosis of diabetes at recruitment as those who did not self-report diabetes or had no indications of diabetes in their primary care records before recruitment. For participants with undiagnosed diabetes, the team calculated the time that it took to receive a clinical diagnosis in their primary care records, defined as the first diagnosis code for diabetes, an HbA1c of at least 48 mmol/mol (6.5%), or a prescription for glucose-lowering medication.

The investigators reported that within the cohort, 2,022, or 1%, had undiagnosed diabetes on screening by HbA1c. Compared with those with an HbA1c of less than 48 mmol/mol, individuals with an HbA1c of at least 48 mmol/mol on screening were statistically older (mean age, 61 years versus 58 years) had obesity (mean BMI, 31 kg/m2 versus 26.6 kg/m2) and were more frequently men versus women (60% versus 45%). Of the 82% of participants with undiagnosed diabetes who had primary care records covering the period after recruitment, median time to clinical diagnosis was 2.3 years, with 23% not diagnosed at 5-year follow-up.

Katie Young, PhD, a postdoctoral research associate and lead author of the study, said, “The fact that, on average, screening identified these people two years earlier than their doctors was quite surprising to us and suggests that screening could improve patient outcomes by allowing lifestyle interventions and diabetes treatment to begin much earlier.” The study was presented at the European Association for the Study of Diabetes virtual annual meeting held 21-25, September, 2020.

Related Links:
University of Exeter Medical School


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
POC Immunoassay Analyzer
Procise DX
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:Schematic illustration of plasmonic microarray–based KRAS mutation detection from colorectal cancer patients. (Lee, J.Y., Mun, C.W., Kim, E.R. et al. npj Precision Oncology, 2026. https://doi.org/10.1038/s41698-026-01452-8)

Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations

Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.